Study S000772

Efficacy and Safety of HS-20094, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients With Type 2 Diabetes: a Randomized, Placebo-controlled and Active Comparator-controlled Phase 2 Trial

ClinicalTrials.gov record

Registration

Registration: NCT06901648
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 275
Start: 2024-02-06
Primary completion: 2025-03-07
Lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:HS-20094; DRUG:Dulaglutide; DRUG:Palcebo
Results posted: FALSE

Registered primary outcomes

The change of HbA1c in the patients [From baseline to week 32]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.